BBRI hit with Downgrade
December 15th, 2010
No comments
Moody’s hit Boston Biomedical Research Institute’s (BBRI) credit rating with a downgrade, Read more…
Archive
Archive for the ‘Stem Cell Technology’ Category
Chairman and CEO William M. Caldwell IV dies, Advanced Cell Technology (ACTC.OB)
December 14th, 2010
No comments
It is with profound sorrow the passing of Chairman and Chief Executive Officer, William M. Caldwell IV. Read more…
Suspending CIRM’s Nominating Vote?
December 14th, 2010
No comments
Calling the process of selecting a chairman for the state’s $3B stem cell research funding agency “fundamentally flawed,” Read more…
Suppressing a Protein in the Blood, Key to Leukemia
December 14th, 2010
No comments
Leukemia can be tackled by “taming” rogue blood cells that fuel the disease. Read more…
Categories: leukemia, Stem Cell Technology, Suppressing a protein in the blood
Strategic Equity Agreement closes, Astellas Pharma and Cytori Therapeutics (CYTX)
December 14th, 2010
No comments
CYTX and Astellas Pharma has closed the strategic equity agreement Read more…
Delivering Stem Cells directly to damaged Hearts
December 14th, 2010
No comments
Researchers may have found a way to repair cardiac muscle that has been damaged by a heart attack Read more…
$25M Common Stock Financing Agreement, International Stem Cell Corporation (ISCO.OB)
December 14th, 2010
No comments
ISCO.OB entered into an agreement with Aspire Capital Fund, LLC, to provide up to $25M of equity capital over 3 years. Read more…
Categories: Financing, NASDAQ: ISCO.OB, Stem Cell Technology
£10M Funding, ReNeuron (LON: RENE)
December 13th, 2010
No comments
RENE will place 181.3M shares in 3 separate tranches at a price of 5.5 pence, a 17% discount to the closing price on 12/10/10 of 6.6 pence raising £10M from investors. Read more…
Categories: Financing, Independent Equity Research, LON: RENE, Reneuron Group, Stem Cell Technology
Stem Cells generate Pancreatic Cells and Intestinal Tissue
December 13th, 2010
No comments
Stem cells can be transformed into the pancreatic cells needed to treat diabetes and into complex layers of intestinal tissue. Read more…
Categories: Diabetes, Intestinal Tissue, Stem Cell Technology
Warrant Distribution to Shareholders, BioTime (AMEX: BTX)
December 10th, 2010
No comments
BTX plans to distribute new common share purchase warrants to the holders of BTX’s common shares. Read more…
Categories: AMEX: BTX, purchase warrants offered, Stem Cell Technology
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.